Research programme: pain therapeutics and companion diagnostics - Genentech/Xenon Pharmaceuticals

Drug Profile

Research programme: pain therapeutics and companion diagnostics - Genentech/Xenon Pharmaceuticals

Alternative Names: XEN-907

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xenon Pharmaceuticals
  • Developer Genentech; Xenon Pharmaceuticals
  • Class Diagnostic agents; Small molecules
  • Mechanism of Action Nav1.7-voltage-gated-sodium-channel-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Pain(Diagnosis) in USA (PO)
  • 15 Mar 2016 Xenon and Genentech extends the two ongoing collaborations to identify new pain targets and therapeutics
  • 11 Jan 2012 Early research in Pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top